{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:41:04Z","timestamp":1787701264768,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022YFC2604000"],"award-info":[{"award-number":["2022YFC2604000"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.imj.2025.100215","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T01:40:16Z","timestamp":1762393216000},"page":"100215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Beyond monotherapy: Combination therapies for HIV-1 cure through joint application of neutralizing antibodies, genome editing, and reservoir management"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6580-7542","authenticated-orcid":false,"given":"Qiongbin","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.imj.2025.100215_bib0001","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/COH.0000000000000859","article-title":"Gaining momentum: stem cell therapies for HIV cure","volume":"19","author":"Buck","year":"2024","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"10.1016\/j.imj.2025.100215_bib0002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41579-024-01010-8","article-title":"Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure","volume":"22","author":"Armani-Tourret","year":"2024","journal-title":"Nat Rev Microbiol"},{"issue":"10485","key":"10.1016\/j.imj.2025.100215_bib0003","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(25)00405-2","article-title":"Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study","volume":"405","author":"Jogiraju","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.imj.2025.100215_bib0004","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00018-022-04421-z","article-title":"HIV cure strategies: which ones are appropriate for Africa?","volume":"79","author":"Abana","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10.1016\/j.imj.2025.100215_bib0005","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3018(23)00264-3","article-title":"Prophylactic HIV-1 vaccine trials: past, present, and future","volume":"11","author":"Nkolola","year":"2024","journal-title":"Lancet HIV"},{"issue":"4","key":"10.1016\/j.imj.2025.100215_bib0006","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.chom.2020.03.018","article-title":"Env exceptionalism: why are HIV-1 env glycoproteins atypical immunogens?","volume":"27","author":"Klasse","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"10","key":"10.1016\/j.imj.2025.100215_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012558","article-title":"Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes","volume":"20","author":"Brinkkemper","year":"2024","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0008","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41467-022-28363-z","article-title":"Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer","volume":"13","author":"Xu","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.imj.2025.100215_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114518","article-title":"Design of soluble HIV-1 envelope trimers free of covalent gp120-gp41 bonds with prevalent native-like conformation","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.imj.2025.100215_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1426232","article-title":"mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies","volume":"15","author":"Guenaga","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93702-x","article-title":"HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth","volume":"11","author":"Fries","year":"2021","journal-title":"Sci Rep"},{"issue":"6697","key":"10.1016\/j.imj.2025.100215_bib0012","doi-asserted-by":"crossref","first-page":"eadk0582","DOI":"10.1126\/science.adk0582","article-title":"mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies","volume":"384","author":"Xie","year":"2024","journal-title":"Science"},{"issue":"95","key":"10.1016\/j.imj.2025.100215_bib0013","doi-asserted-by":"crossref","first-page":"eadn0622","DOI":"10.1126\/sciimmunol.adn0622","article-title":"mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models","volume":"9","author":"Wang","year":"2024","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/vaccines6010010","article-title":"Virus-like-vaccines against hiv","volume":"6","author":"Andersson","year":"2018","journal-title":"Vaccines"},{"issue":"6759","key":"10.1016\/j.imj.2025.100215_bib0015","doi-asserted-by":"crossref","first-page":"eadr8382","DOI":"10.1126\/science.adr8382","article-title":"Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans","volume":"389","author":"Willis","year":"2025","journal-title":"Science"},{"issue":"98","key":"10.1016\/j.imj.2025.100215_bib0016","doi-asserted-by":"crossref","first-page":"eadk9550","DOI":"10.1126\/sciimmunol.adk9550","article-title":"Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site","volume":"9","author":"Caniels","year":"2024","journal-title":"Sci Immunol"},{"issue":"12","key":"10.1016\/j.imj.2025.100215_bib0017","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","article-title":"Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial","volume":"30","author":"Julg","year":"2024","journal-title":"Nat Med"},{"issue":"6288","key":"10.1016\/j.imj.2025.100215_bib0018","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.imj.2025.100215_bib0019","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/v16081296","article-title":"Triple combinations of AAV9-vectors encoding anti-HIV bNAbs provide long-term in vivo expression of human IgG effectively neutralizing pseudoviruses from HIV-1 global panel","volume":"16","author":"Shipulin","year":"2024","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.imj.2025.100215_bib0020","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41590-023-01741-5","article-title":"Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells","volume":"25","author":"Board","year":"2024","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.imj.2025.100215_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009732","article-title":"Germinal Center T follicular helper (GC-Tfh) cell impairment in chronic HIV infection involves c-maf signaling","volume":"17","author":"Chakhtoura","year":"2021","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/j.imj.2025.100215_bib0022","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/COH.0000000000000819","article-title":"Guiding HIV-1 vaccine development with preclinical nonhuman primate research","volume":"18","author":"Counts","year":"2023","journal-title":"Curr Opin HIV AIDS"},{"issue":"99","key":"10.1016\/j.imj.2025.100215_bib0023","doi-asserted-by":"crossref","first-page":"eadl3755","DOI":"10.1126\/sciimmunol.adl3755","article-title":"Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response","volume":"9","author":"Bhagchandani","year":"2024","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0024","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41541-024-01038-0","article-title":"Neutralizing antibodies elicited in macaques recognize V3 residues on altered conformations of HIV-1 Env trimer","volume":"9","author":"DeLaitsch","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"10","key":"10.1016\/j.imj.2025.100215_bib0025","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0026","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/biomedicines12010119","article-title":"Increasing gene editing efficiency via CRISPR\/Cas9- or Cas12a-mediated knock-In in primary human T cells","volume":"12","author":"Kruglova","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.imj.2025.100215_bib0027","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3390\/v14091902","article-title":"Synthetic gRNA\/Cas9 ribonucleoprotein inhibits HIV reactivation and replication","volume":"14","author":"Khanal","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13072-024-00564-4","article-title":"The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review","volume":"18","author":"Letchumanan","year":"2025","journal-title":"Epigenetics Chromatin"},{"issue":"19","key":"10.1016\/j.imj.2025.100215_bib0029","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217887120","article-title":"CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice","volume":"120","author":"Dash","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.imj.2025.100215_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2022.108954","article-title":"Towards a new combination therapy with vectored immunoprophylaxis for HIV: modeling \"shock and kill\" strategy","volume":"355","author":"Deng","year":"2023","journal-title":"Math Biosci"},{"key":"10.1016\/j.imj.2025.100215_bib0031","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.2147\/IJN.S401304","article-title":"Nanodepots encapsulating a latency reversing agent and broadly neutralizing antibody enhance natural killer cell cytotoxicity against an in vitro model of latent HIV","volume":"18","author":"Ghofrani","year":"2023","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"10.1016\/j.imj.2025.100215_bib0032","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.imj.2025.100215_bib0033","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.it.2020.04.003","article-title":"Rinse and replace': boosting T cell turnover to reduce HIV-1 reservoirs","volume":"41","author":"Grossman","year":"2020","journal-title":"Trends Immunol"},{"issue":"11","key":"10.1016\/j.imj.2025.100215_bib0034","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1084\/jem.20071211","article-title":"Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus","volume":"204","author":"Kwissa","year":"2007","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0035","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1038\/s41467-025-59398-7","article-title":"BRD4 modulator ZL0580 and LEDGINs additively b in vivo HIV-1 transcription","volume":"16","author":"Pellaers","year":"2025","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.imj.2025.100215_bib0036","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0037","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov"},{"issue":"5","key":"10.1016\/j.imj.2025.100215_bib0038","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/v15051126","article-title":"Challenges in HIV-1 latent reservoir and target cell quantification in CAR-T cell and other lentiviral gene modifying HIV cure strategies","volume":"15","author":"Buck","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0039","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/v15010202","article-title":"Development of HIV-resistant CAR T cells by CRISPR\/cas-mediated CAR integration into the CCR5 locus","volume":"15","author":"Rothemejer","year":"2023","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.imj.2025.100215_bib0040","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.imj.2025.100215_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108399","article-title":"The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases","volume":"245","author":"Retnakumar","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.imj.2025.100215_bib0042","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185489","article-title":"Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo","volume":"135","author":"Mu","year":"2025","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.imj.2025.100215_bib0043","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa223","article-title":"Challenges and opportunities of using adoptive T-cell therapy as part of an HIV cure strategy","volume":"223","author":"Zhou","year":"2021","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.imj.2025.100215_bib0044","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61626-x","article-title":"CRISPR\/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1","volume":"14","author":"Khamaikawin","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.imj.2025.100215_bib0045","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1038\/s41591-024-03277-z","article-title":"Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells","volume":"30","author":"S\u00e1ez-Ciri\u00f3n","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.imj.2025.100215_bib0046","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1038\/mtna.2015.42","article-title":"CCR5 disruption in induced pluripotent stem cells using CRISPR\/Cas9 provides selective resistance of immune cells to CCR5-tropic HIV-1 virus","volume":"4","author":"Kang","year":"2015","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Infectious Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772431X25000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772431X25000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T07:46:31Z","timestamp":1766389591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772431X25000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2772431X25000541"],"URL":"https:\/\/doi.org\/10.1016\/j.imj.2025.100215","relation":{},"ISSN":["2772-431X"],"issn-type":[{"value":"2772-431X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond monotherapy: Combination therapies for HIV-1 cure through joint application of neutralizing antibodies, genome editing, and reservoir management","name":"articletitle","label":"Article Title"},{"value":"Infectious Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imj.2025.100215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100215"}}